207 related articles for article (PubMed ID: 23372725)
21. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
Liu CC; Chow YH; Chong P; Klein M
Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
Huo C; Yang J; Lei L; Qiao L; Xin J; Pan Z
Vaccine; 2017 Dec; 35(52):7322-7330. PubMed ID: 29129453
[TBL] [Abstract][Full Text] [Related]
23. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.
Hu Y; Zeng G; Chu K; Zhang J; Han W; Zhang Y; Li J; Zhu F
Hum Vaccin Immunother; 2018 Jun; 14(6):1517-1523. PubMed ID: 29482422
[TBL] [Abstract][Full Text] [Related]
24. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease.
Tsou YL; Lin YW; Shao HY; Yu SL; Wu SR; Lin HY; Liu CC; Huang C; Chong P; Chow YH
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003692. PubMed ID: 25855976
[TBL] [Abstract][Full Text] [Related]
25. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
[TBL] [Abstract][Full Text] [Related]
26. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model.
Jin WP; Lu J; Zhang XY; Wu J; Wei ZN; Mai JY; Qian SS; Yu YT; Meng SL; Wang ZJ; Shen S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408178
[TBL] [Abstract][Full Text] [Related]
28. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.
Tambyah PA; Oon J; Asli R; Kristanto W; Hwa SH; Vang F; Karwal L; Fuchs J; Santangelo JD; Gordon GS; Thomson C; Rao R; Dean H; Das SC; Stinchcomb DT
Vaccine; 2019 Jul; 37(31):4344-4353. PubMed ID: 31230881
[TBL] [Abstract][Full Text] [Related]
29. Intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar protective immunity to intramuscular inoculation of a full dose of an Al(OH)
Li M; Duan Y; Yang X; Yang Q; Pang B; Wang Y; Ren T; Wang X; Zhao Z; Liu S
Vaccine; 2017 Jun; 35(30):3709-3717. PubMed ID: 28576572
[TBL] [Abstract][Full Text] [Related]
30. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
[TBL] [Abstract][Full Text] [Related]
31. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge.
Lin YL; Chow YH; Huang LM; Hsieh SM; Cheng PY; Hu KC; Chiang BL
Sci Rep; 2018 Jul; 8(1):10713. PubMed ID: 30013088
[TBL] [Abstract][Full Text] [Related]
32. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines.
Klein MH
Expert Rev Vaccines; 2015 Mar; 14(3):337-40. PubMed ID: 25536888
[TBL] [Abstract][Full Text] [Related]
33. Enterovirus 71 vaccine: close but still far.
Zhang D; Lu J; Lu J
Int J Infect Dis; 2010 Sep; 14(9):e739-43. PubMed ID: 20400350
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.
Li YP; Liang ZL; Xia JL; Wu JY; Wang L; Song LF; Mao QY; Wen SQ; Huang RG; Hu YS; Yao X; Miao X; Wu X; Li RC; Wang JZ; Yin WD
J Infect Dis; 2014 Jan; 209(1):46-55. PubMed ID: 23922377
[TBL] [Abstract][Full Text] [Related]
35. Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges.
Yan Q; Wu L; Chen L; Qin Y; Pan Z; Chen M
Vaccine; 2016 Jul; 34(35):4196-4204. PubMed ID: 27373596
[TBL] [Abstract][Full Text] [Related]
36. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants.
Mao QY; Liao XY; Yu X; Li N; Zhu FC; Zeng Y; Liang ZL; Li FX; Wang JZ; Lu FM; Zhuang H
Chin Med J (Engl); 2010 Jul; 123(13):1679-84. PubMed ID: 20819628
[TBL] [Abstract][Full Text] [Related]
37. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
38. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.
Hu YM; Wang X; Wang JZ; Wang L; Zhang YJ; Chang L; Liang ZL; Xia JL; Dai QG; Hu YL; Mao QY; Zhu FC; Song YF; Gao F; Chen JT
Clin Vaccine Immunol; 2013 Dec; 20(12):1805-11. PubMed ID: 24108780
[TBL] [Abstract][Full Text] [Related]
40. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.
Zhu W; Jin P; Li JX; Zhu FC; Liu P
Expert Rev Vaccines; 2017 Sep; 16(9):945-949. PubMed ID: 28548626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
